3 Health Care Stocks Pushing The Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 79 points (-0.5%) at 16,635 as of Friday, Aug. 15, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,072 issues advancing vs. 1,895 declining with 174 unchanged.

The Health Care sector currently sits down 0.7% versus the S&P 500, which is down 0.3%. Top gainers within the sector include Agilent Technologies ( A), up 3.7%, Gilead ( GILD), up 1.6%, Actavis ( ACT), up 1.4%, Allergan ( AGN), up 1.4% and Valeant Pharmaceuticals International ( VRX), up 1.2%. On the negative front, top decliners within the sector include Smith & Nephew ( SNN), down 2.2%, DaVita HealthCare Partners ( DVA), down 1.5%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.3%, WellPoint ( WLP), down 1.1% and Stryker Corporation ( SYK), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Jazz Pharmaceuticals ( JAZZ) is one of the companies pushing the Health Care sector higher today. As of noon trading, Jazz Pharmaceuticals is up $3.99 (2.8%) to $148.29 on average volume. Thus far, 576,801 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 869,400 shares. The stock has ranged in price between $144.46-$150.79 after having opened the day at $145.55 as compared to the previous trading day's close of $144.30.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals has a market cap of $8.7 billion and is part of the drugs industry. Shares are up 14.0% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Jazz Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Salix Pharmaceuticals ( SLXP) is up $3.74 (2.8%) to $136.98 on average volume. Thus far, 601,158 shares of Salix Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $133.43-$137.09 after having opened the day at $133.96 as compared to the previous trading day's close of $133.23.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. Salix Pharmaceuticals has a market cap of $8.3 billion and is part of the drugs industry. Shares are up 45.7% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Salix Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Salix Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Salix Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, HCA Holdings ( HCA) is up $0.45 (0.7%) to $67.65 on light volume. Thus far, 1.1 million shares of HCA Holdings exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $67.26-$67.99 after having opened the day at $67.35 as compared to the previous trading day's close of $67.20.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

HCA Holdings, Inc., through its subsidiaries, provides health care services. HCA Holdings has a market cap of $28.7 billion and is part of the health services industry. Shares are up 39.1% year-to-date as of the close of trading on Thursday. Currently there are 16 analysts who rate HCA Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates HCA Holdings as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, revenue growth, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full HCA Holdings Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Dow Tumbles as Trump Calls Off North Korea Summit

Dow Tumbles as Trump Calls Off North Korea Summit

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Stocks Could Easily Crater Into Memorial Day Weekend

Stocks Could Easily Crater Into Memorial Day Weekend

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Celgene Shares Rise on Plans to Increase Stock Buybacks

Celgene Shares Rise on Plans to Increase Stock Buybacks